Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 10 studies | 20% ± 6% | |
| smooth muscle cell | 9 studies | 19% ± 3% | |
| endothelial cell | 8 studies | 24% ± 7% | |
| pericyte | 8 studies | 24% ± 5% | |
| plasmacytoid dendritic cell | 5 studies | 23% ± 3% | |
| myofibroblast cell | 3 studies | 21% ± 5% | |
| epithelial cell | 3 studies | 34% ± 4% | |
| basal cell | 3 studies | 23% ± 5% | |
| ciliated cell | 3 studies | 28% ± 8% | |
| glutamatergic neuron | 3 studies | 21% ± 5% | |
| natural killer cell | 3 studies | 18% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| lung | 4 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 5990.05 | 180 / 180 | 100% | 146.83 | 430 / 430 |
| prostate | 100% | 3650.26 | 245 / 245 | 100% | 62.95 | 501 / 502 |
| esophagus | 100% | 3568.88 | 1444 / 1445 | 99% | 65.94 | 182 / 183 |
| breast | 100% | 5722.65 | 459 / 459 | 99% | 63.23 | 1109 / 1118 |
| lung | 99% | 3995.16 | 575 / 578 | 100% | 51.35 | 1150 / 1155 |
| thymus | 100% | 3854.30 | 652 / 653 | 99% | 63.55 | 600 / 605 |
| skin | 100% | 4014.71 | 1809 / 1809 | 99% | 57.56 | 467 / 472 |
| uterus | 100% | 4251.18 | 170 / 170 | 98% | 50.64 | 450 / 459 |
| bladder | 100% | 4920.48 | 21 / 21 | 98% | 47.02 | 494 / 504 |
| stomach | 100% | 2872.72 | 359 / 359 | 98% | 32.90 | 279 / 286 |
| adrenal gland | 100% | 4619.61 | 258 / 258 | 97% | 67.72 | 224 / 230 |
| brain | 97% | 2494.83 | 2563 / 2642 | 100% | 53.67 | 704 / 705 |
| pancreas | 98% | 1823.70 | 323 / 328 | 98% | 37.94 | 175 / 178 |
| intestine | 100% | 4436.26 | 965 / 966 | 96% | 25.92 | 504 / 527 |
| kidney | 100% | 3214.26 | 89 / 89 | 93% | 30.58 | 840 / 901 |
| liver | 100% | 1881.66 | 226 / 226 | 68% | 15.20 | 277 / 406 |
| adipose | 100% | 4685.64 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 3606.62 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 47.88 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 31.87 | 1 / 1 |
| blood vessel | 100% | 4555.55 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| heart | 97% | 2628.53 | 833 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 42.08 | 77 / 80 |
| muscle | 93% | 1696.89 | 749 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 78% | 3294.62 | 722 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 76% | 18.61 | 22 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0046543 | Biological process | development of secondary female sexual characteristics |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0007399 | Biological process | nervous system development |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0046872 | Molecular function | metal ion binding |
| Gene name | IRF2BPL |
| Protein name | Probable E3 ubiquitin-protein ligase IRF2BPL (EC 2.3.2.27) (Enhanced at puberty protein 1) (Interferon regulatory factor 2-binding protein-like) |
| Synonyms | My039 C14orf4 EAP1 KIAA1865 |
| Description | FUNCTION: Probable E3 ubiquitin protein ligase involved in the proteasome-mediated ubiquitin-dependent degradation of target proteins . Through the degradation of CTNNB1, functions downstream of FOXF2 to negatively regulate the Wnt signaling pathway . Probably plays a role in the development of the central nervous system and in neuronal maintenance (Probable). Also acts as a transcriptional regulator of genes controlling female reproductive function. May play a role in gene transcription by transactivating GNRH1 promoter and repressing PENK promoter (By similarity). . |
| Accessions | ENST00000238647.5 Q9H1B7 |